Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (VALFRID)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Lund University Hospital
Sponsor:
Collaborator:
Valcuria
Information provided by (Responsible Party):
Lund University Hospital
ClinicalTrials.gov Identifier:
NCT01622439
First received: June 12, 2012
Last updated: November 3, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2015
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)